

HCmed joins Wuxi life science innovation park

09 September 2019 | News

HCmed specializes on the development of handheld devices for inhaled drug delivery therapy.



Supported by the idea of garnering global wisdom to improve the healthcare system in China, Wuxi Municipal Government, Wuxi High-tech District, and AstraZeneca, as a founding partner, officially inaugurated Wuxi International Life Science Innovation Park on September 7, 2019.

The new life science park sets a world-class ecosystem where local and international companies, government, and medical and academic institutions will be able to join forces to generate innovative advances in medical research.

Taiwan based HCmed Innovations Co., Ltd. (HCmed) has been selected as the first batch companies to join Wuxi International Life Science Innovation Park. HCmed specializes on the development of handheld devices for inhaled drug delivery therapy. It focuses on the delivery of high value therapeutic drugs by providing a customizable platform that increases nebulization performance, ensuring medications are efficiently carried into the lower tract of the lungs and enabling a well-controlled treatment for respiratory diseases.

Chronic respiratory diseases have been categorized by the World Health Organization as one of the four major chronic diseases. In Mainland China, the prevalence of respiratory diseases such as asthma has highly increased in recent years. It is expected that the number of people suffering from these conditions will exceed 60 million. In 2017, The market for asthma and COPD was estimated at RMB 44 billion in Mainland China, including long-term use of inhaled corticosteroids (ICS) and bronchodilators.

Pulmicort Respules (budesonide suspension) is a well-known inhaled corticosteroid produced by AstraZeneca with an annual market size of over RMB 6 billion in China. The nature of its suspension formulation makes it difficult to be nebulized by most mesh nebulizers, while mesh clogging is often described as a recurrent issue. The innovative delivery technology and easy-to-clean feature of HCmed's mesh nebulizer can overcome the barriers of nebulizing suspensions, generating a large potential market in the future.